Yes. Buprenorphine is one of the 76 compounds in the LabX LC-MS/MS confirmation panel, reported as detected at or above 5 ng/mL. Buprenorphine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
Buprenorphine is a partial opioid agonist: it activates opioid receptors, but with a ceiling on some effects. The body converts it into norbuprenorphine.
Also known as or found in: Suboxone, Sublocade.
Buprenorphine is prescribed to treat opioid use disorder, often combined with naloxone, and in some forms for pain.
Buprenorphine is measured by liquid chromatography with tandem mass spectrometry (LC-MS/MS), which separates the compounds in a sample and identifies each one by its mass. That is different from a rapid screen, which reacts to a family of drugs and can occasionally react to a related substance. The laboratory reports Buprenorphine as detected when its concentration is at or above the cut-off of 5 ng/mL, within a reportable range of 5β1,000 ng/mL. It is one of 5 compounds in the opioid treatment and reversal family on the 76-drug confirmation panel.
The laboratory's confirmation report lists an approximate detection window of 0.5 to 1 day for Buprenorphine. Treat that as a rough guide only: how long any compound stays measurable varies with the amount taken, how often it is used, body composition, metabolism, kidney and liver function, and hydration. A laboratory result cannot be used to work out when a substance was taken.
Buprenorphine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
In treatment monitoring, buprenorphine is usually assessed together with norbuprenorphine, because the metabolite shows the medicine was taken rather than added to the sample.
Medicines used to treat opioid and alcohol use disorder or to reverse an overdose, with their metabolites, as monitored in treatment programs.
Yes. Buprenorphine is one of the 76 compounds in the LabX LC-MS/MS confirmation panel, reported as detected at or above 5 ng/mL. Buprenorphine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
LabX reports Buprenorphine as detected at or above 5 ng/mL, and the method's reportable range is 5β1,000 ng/mL. A result below the cut-off is reported as not detected; it does not prove none was present.
The laboratory lists an approximate window of 0.5 to 1 day, but it varies with dose, frequency of use, metabolism and hydration, and cannot be used to tell when something was taken.
Buprenorphine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
Buprenorphine is prescribed to treat opioid use disorder, often combined with naloxone, and in some forms for pain.
Terms on this page: metabolite Β· cut-off Β· detection window Β· presumptive result Β· confirmation test. More questions: LabX answers.
Test for Buprenorphine and 75 other compounds
12-panel urine $89 or fingerstick blood $99, plus the 76-drug LC-MS/MS confirmation for +$89.
At-home drug tests and test kits are not currently available to addresses in New York, New Jersey, Rhode Island or California. Results are not a diagnosis β review them with a licensed physician.
Medical disclaimer. LabX Diagnostics and Vantage provide laboratory testing only. Test results and information on this site are for informational purposes and are not medical advice, diagnosis or treatment. Always consult a licensed physician or other qualified healthcare provider about your results and before making any health decision. If you think you may have a medical emergency, call 911. Read the full disclaimer.
Learn: 76-drug confirmation list · Drug library · Answers · How it works · Is LabX legit? · Glossary
